Current Report Filing (8-k)
September 07 2022 - 4:38PM
Edgar (US Regulatory)
false
0001653821
0001653821
2022-09-07
2022-09-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): September 7, 2022
CEN BIOTECH, INC.
(Exact name of registrant as specified in its charter)
Ontario, Canada
|
000-55557
|
-
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification
Number)
|
300-3295 Quality Way
Windsor, Ontario
Canada
N8T 3R9
(Address of principal executive offices, including zip code)
(519) 419-4958
(Registrant’s telephone number, including area code)
Not applicable.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
None
|
|
N/A
|
|
N/A
|
☑
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
Item 7.01 Regulation FD Disclosure.
On September 7, 2022, CEN Biotech Inc. (the “Company”) issued a press release (the “Press Release”). The Press Release announces the commencement of trading of the Company’s common shares on the OTCQB Venture Market® beginning on September 8, 2022 and also provides a business update. The Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in the Press Release is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
|
|
Description
|
99.1**
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
**Furnished herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
CEN Biotech, Inc.
|
|
|
|
|
Date: September 7, 2022
|
By:
|
/s/ Brian S. Payne
|
|
|
Brian S. Payne
|
|
|
Chief Executive Officer (principal
executive officer)
|
CEN Biotech (CE) (USOTC:CENBF)
Historical Stock Chart
From Nov 2024 to Dec 2024
CEN Biotech (CE) (USOTC:CENBF)
Historical Stock Chart
From Dec 2023 to Dec 2024